Bioequivalence Study of Two Ibuprofen Arginine Formulations in Healthy Chinese Subjects Under Fed Conditions
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70083 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Yiyang Ying und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China. Hauptthemen laut MEDLINE: Ibuprofen, Arginine, Anti-Inflammatory Agents, Non-Steroidal, Drugs, Generic. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Key Research and Development Program of Zhejiang Province.
Abstract (Originalsprache)
To evaluate the bioequivalence and safety of a generic ibuprofen arginine formulation (T) compared to Sibide (R) in healthy Chinese subjects under fed conditions, a randomized, open‐label, single‐dose, two‐period, two‐sequence crossover study was conducted. Twenty‐eight eligible healthy subjects received a single 400 mg dose of either the T or R formulation following a standardized high‐fat meal, with a 3‐day washout period between doses. Plasma ibuprofen concentrations were quantified using a validated LC‐MS/MS method. Pharmacokinetic parameters, including C max , AUC 0–t , and AUC 0–∞ , were calculated using non‐compartmental analysis. Bioequivalence was assessed based on the geometric mean ratios (GMRs) and 90% confidence intervals (CIs) derived from ANOVA. All 28 enrolled subjects completed the study. The GMRs (90% CIs) for C max , AUC 0–t, and AUC 0–∞ were 107.03% (100.02%–114.52%), 100.99% (98.46%–103.58%), and 100.95% (98.24%–103.74%), respectively. All 90% CIs fell entirely within the regulatory bioequivalence acceptance range of 0.80–1.25. Both formulations were well tolerated; adverse events were mild to moderate, and no serious adverse events were reported. Thus, the T formulation of ibuprofen arginine demonstrated bioequivalence to the R formulation in healthy Chinese subjects under fed conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.
- Department of Laboratory Medicine, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
- School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.
- Clinical Research Center, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
- Zhejiang Key Laboratory of Zero Magnetic Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Key Research and Development Program of Zhejiang Province
- Education Department Foundation of Zhejiang Province
Zitieren
APA
Ying, Y., Huang, C., Xu, L., Wu, Y., Cai, S., Ye, L., Huang, X., Wang, L., & Wang, Y. (2026). Bioequivalence Study of Two Ibuprofen Arginine Formulations in Healthy Chinese Subjects Under Fed Conditions. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70083
Vancouver
Ying Y, Huang C, Xu L, Wu Y, Cai S, Ye L, et al. Bioequivalence Study of Two Ibuprofen Arginine Formulations in Healthy Chinese Subjects Under Fed Conditions. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70083
BibTeX
@article{Ying2026,
author = {Ying, Yiyang and Huang, Chunqi and Xu, Li and Wu, Yi and Cai, Shufan and Ye, Lijun and Huang, Xiangxin and Wang, Lin and Wang, Ying},
title = {Bioequivalence Study of Two Ibuprofen Arginine Formulations in Healthy Chinese Subjects Under Fed Conditions},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70083}
}
EUVIMED